Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Express Scripts
McKesson
Harvard Business School
Boehringer Ingelheim

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR REGORAFENIB

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Regorafenib

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01002378 The Effect of Food (High Fat and Low Fat Breakfast) on the Pharmacokinetics of Regorafenib Completed Bayer Phase 1 2009-10-01 An open label, three way crossover study to determine the effect of a high fat breakfast or a low fat breakfast on the pharmacokinetics of a single dose of regorafenib.
NCT01068769 Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor Active, not recruiting Bayer Phase 2 2010-02-01 The purpose of this research study is to determine the safety and activity of regorafenib in participants with advanced gastrointestinal stromal tumor (GIST) if the standard approved therapies, imatinib and sunitinib, have failed to control the disease. Regorafenib is a drug that blocks abnormally active signaling enzymes called "tyrosine kinases" which are important to the growth of GIST. This "tyrosine kinase inhibition" is similar to the way that both imatinib and sunitinib work; however, regorafenib blocks certain additional signaling pathways that are not blocked by imatinib or sunitinib. Regorafenib has been not been tested in GIST participants before this research study.
NCT01068769 Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor Active, not recruiting Brigham and Women's Hospital Phase 2 2010-02-01 The purpose of this research study is to determine the safety and activity of regorafenib in participants with advanced gastrointestinal stromal tumor (GIST) if the standard approved therapies, imatinib and sunitinib, have failed to control the disease. Regorafenib is a drug that blocks abnormally active signaling enzymes called "tyrosine kinases" which are important to the growth of GIST. This "tyrosine kinase inhibition" is similar to the way that both imatinib and sunitinib work; however, regorafenib blocks certain additional signaling pathways that are not blocked by imatinib or sunitinib. Regorafenib has been not been tested in GIST participants before this research study.
NCT01068769 Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor Active, not recruiting Fox Chase Cancer Center Phase 2 2010-02-01 The purpose of this research study is to determine the safety and activity of regorafenib in participants with advanced gastrointestinal stromal tumor (GIST) if the standard approved therapies, imatinib and sunitinib, have failed to control the disease. Regorafenib is a drug that blocks abnormally active signaling enzymes called "tyrosine kinases" which are important to the growth of GIST. This "tyrosine kinase inhibition" is similar to the way that both imatinib and sunitinib work; however, regorafenib blocks certain additional signaling pathways that are not blocked by imatinib or sunitinib. Regorafenib has been not been tested in GIST participants before this research study.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Regorafenib

Condition Name

Condition Name for Regorafenib
Intervention Trials
Metastatic Colorectal Cancer 19
Colorectal Neoplasms 17
Colorectal Cancer 13
Gastrointestinal Stromal Tumors 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Regorafenib
Intervention Trials
Colorectal Neoplasms 66
Gastrointestinal Stromal Tumors 17
Adenocarcinoma 10
Carcinoma 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Regorafenib

Trials by Country

Trials by Country for Regorafenib
Location Trials
United States 381
Italy 65
Germany 56
Japan 46
China 44
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Regorafenib
Location Trials
California 24
Florida 21
New York 21
North Carolina 18
Texas 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Regorafenib

Clinical Trial Phase

Clinical Trial Phase for Regorafenib
Clinical Trial Phase Trials
Phase 4 4
Phase 3 15
Phase 2/Phase 3 2
[disabled in preview] 77
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Regorafenib
Clinical Trial Phase Trials
Recruiting 72
Not yet recruiting 27
Active, not recruiting 18
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Regorafenib

Sponsor Name

Sponsor Name for Regorafenib
Sponsor Trials
Bayer 69
National Cancer Institute (NCI) 9
Asan Medical Center 8
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Regorafenib
Sponsor Trials
Other 128
Industry 107
NIH 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKesson
AstraZeneca
Dow
Medtronic
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.